Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Study of the efficacy, biodistribution, and safety profile of therapeutic gutless adenovirus vectors as a prelude to a phase I clinical trial for glioblastoma.

Muhammad AK, Puntel M, Candolfi M, Salem A, Yagiz K, Farrokhi C, Kroeger KM, Xiong W, Curtin JF, Liu C, Lawrence K, Bondale NS, Lerner J, Baker GJ, Foulad D, Pechnick RN, Palmer D, Ng P, Lowenstein PR, Castro MG.

Clin Pharmacol Ther. 2010 Aug;88(2):204-13. doi: 10.1038/clpt.2009.260. Epub 2010 Feb 17.

2.

Safety profile, efficacy, and biodistribution of a bicistronic high-capacity adenovirus vector encoding a combined immunostimulation and cytotoxic gene therapy as a prelude to a phase I clinical trial for glioblastoma.

Puntel M, A K M GM, Farrokhi C, Vanderveen N, Paran C, Appelhans A, Kroeger KM, Salem A, Lacayo L, Pechnick RN, Kelson KR, Kaur S, Kennedy S, Palmer D, Ng P, Liu C, Krasinkiewicz J, Lowenstein PR, Castro MG.

Toxicol Appl Pharmacol. 2013 May 1;268(3):318-30. doi: 10.1016/j.taap.2013.02.001. Epub 2013 Feb 9.

3.

A novel bicistronic high-capacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and tet-inducible expression of Flt3L for glioma therapeutics.

Puntel M, Muhammad AK, Candolfi M, Salem A, Yagiz K, Farrokhi C, Kroeger KM, Xiong W, Curtin JF, Liu C, Bondale NS, Lerner J, Pechnick RN, Palmer D, Ng P, Lowenstein PR, Castro MG.

J Virol. 2010 Jun;84(12):6007-17. doi: 10.1128/JVI.00398-10. Epub 2010 Apr 7.

4.

Safety profile of gutless adenovirus vectors delivered into the normal brain parenchyma: implications for a glioma phase 1 clinical trial.

Muhammad AK, Xiong W, Puntel M, Farrokhi C, Kroeger KM, Salem A, Lacayo L, Pechnick RN, Kelson KR, Palmer D, Ng P, Liu C, Lowenstein PR, Castro MG.

Hum Gene Ther Methods. 2012 Aug;23(4):271-84. doi: 10.1089/hgtb.2012.060. Epub 2012 Sep 5.

5.

Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro.

Candolfi M, Pluhar GE, Kroeger K, Puntel M, Curtin J, Barcia C, Muhammad AK, Xiong W, Liu C, Mondkar S, Kuoy W, Kang T, McNeil EA, Freese AB, Ohlfest JR, Moore P, Palmer D, Ng P, Young JD, Lowenstein PR, Castro MG.

Neuro Oncol. 2007 Jul;9(3):245-58. Epub 2007 May 23.

6.

Effectiveness and preclinical safety profile of doxycycline to be used "off-label" to induce therapeutic transgene expression in a phase I clinical trial for glioma.

VanderVeen N, Paran C, Krasinkiewicz J, Zhao L, Palmer D, Hervey-Jumper S, Ng P, Lowenstein PR, Castro MG.

Hum Gene Ther Clin Dev. 2013 Sep;24(3):116-26. doi: 10.1089/humc.2013.139.

7.

Flt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficits.

King GD, Kroeger KM, Bresee CJ, Candolfi M, Liu C, Manalo CM, Muhammad AK, Pechnick RN, Lowenstein PR, Castro MG.

Mol Ther. 2008 Apr;16(4):682-90. doi: 10.1038/mt.2008.18. Epub 2008 Feb 19.

8.

High-capacity adenovirus vector-mediated anti-glioma gene therapy in the presence of systemic antiadenovirus immunity.

King GD, Muhammad AK, Xiong W, Kroeger KM, Puntel M, Larocque D, Palmer D, Ng P, Lowenstein PR, Castro MG.

J Virol. 2008 May;82(9):4680-4. doi: 10.1128/JVI.00232-08. Epub 2008 Feb 20. Erratum in: J Virol. 2008 Jun;82(12):6087.

9.

Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design.

Mineharu Y, King GD, Muhammad AK, Bannykh S, Kroeger KM, Liu C, Lowenstein PR, Castro MG.

Clin Cancer Res. 2011 Jul 15;17(14):4705-18. doi: 10.1158/1078-0432.CCR-11-0915. Epub 2011 Jun 1.

10.

Adenoviral-mediated gene transfer into the canine brain in vivo.

Candolfi M, Kroeger KM, Pluhar GE, Bergeron J, Puntel M, Curtin JF, McNiel EA, Freese AB, Ohlfest JR, Moore P, Lowenstein PR, Castro MG.

Neurosurgery. 2007 Jan;60(1):167-77; discussion 178.

11.

Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression.

Ghulam Muhammad AK, Candolfi M, King GD, Yagiz K, Foulad D, Mineharu Y, Kroeger KM, Treuer KA, Nichols WS, Sanderson NS, Yang J, Khayznikov M, Van Rooijen N, Lowenstein PR, Castro MG.

Clin Cancer Res. 2009 Oct 1;15(19):6113-27. doi: 10.1158/1078-0432.CCR-09-1087. Epub 2009 Sep 29.

12.

Effective high-capacity gutless adenoviral vectors mediate transgene expression in human glioma cells.

Candolfi M, Curtin JF, Xiong WD, Kroeger KM, Liu C, Rentsendorj A, Agadjanian H, Medina-Kauwe L, Palmer D, Ng P, Lowenstein PR, Castro MG.

Mol Ther. 2006 Sep;14(3):371-81. Epub 2006 Jun 23.

13.

Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity.

Candolfi M, Yagiz K, Foulad D, Alzadeh GE, Tesarfreund M, Muhammad AK, Puntel M, Kroeger KM, Liu C, Lee S, Curtin JF, King GD, Lerner J, Sato K, Mineharu Y, Xiong W, Lowenstein PR, Castro MG.

Clin Cancer Res. 2009 Jul 1;15(13):4401-14. doi: 10.1158/1078-0432.CCR-09-0155.

14.

Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model.

King GD, Muhammad AK, Curtin JF, Barcia C, Puntel M, Liu C, Honig SB, Candolfi M, Mondkar S, Lowenstein PR, Castro MG.

Neuro Oncol. 2008 Feb;10(1):19-31. Epub 2007 Dec 13.

15.

Marmosets as a preclinical model for testing "off-label" use of doxycycline to turn on Flt3L expression from high-capacity adenovirus vectors.

VanderVeen N, Paran C, Appelhans A, Krasinkiewicz J, Lemons R, Appelman H, Doherty R, Palmer D, Ng P, Lowenstein PR, Castro MG.

Mol Ther Methods Clin Dev. 2014 Feb 5;1. pii: 10.

16.

HMGB1 mediates endogenous TLR2 activation and brain tumor regression.

Curtin JF, Liu N, Candolfi M, Xiong W, Assi H, Yagiz K, Edwards MR, Michelsen KS, Kroeger KM, Liu C, Muhammad AK, Clark MC, Arditi M, Comin-Anduix B, Ribas A, Lowenstein PR, Castro MG.

PLoS Med. 2009 Jan 13;6(1):e10. doi: 10.1371/journal.pmed.1000010.

17.

Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen.

King GD, Muhammad AK, Larocque D, Kelson KR, Xiong W, Liu C, Sanderson NS, Kroeger KM, Castro MG, Lowenstein PR.

Mol Ther. 2011 Oct;19(10):1793-801. doi: 10.1038/mt.2011.77. Epub 2011 Apr 19.

18.

Preclinical Efficacy and Safety Profile of Allometrically Scaled Doses of Doxycycline Used to Turn "On" Therapeutic Transgene Expression from High-Capacity Adenoviral Vectors in a Glioma Model.

VanderVeen N, Raja N, Yi E, Appelman H, Ng P, Palmer D, Zamler D, Dzaman M, Lowenstein PR, Castro MG.

Hum Gene Ther Methods. 2016 Jun;27(3):98-111. doi: 10.1089/hgtb.2015.168. Epub 2016 Apr 28.

PMID:
27056322
19.

Adenoviral vector-mediated gene therapy for gliomas: coming of age.

Castro MG, Candolfi M, Wilson TJ, Calinescu A, Paran C, Kamran N, Koschmann C, Moreno-Ayala MA, Assi H, Lowenstein PR.

Expert Opin Biol Ther. 2014 Sep;14(9):1241-57. doi: 10.1517/14712598.2014.915307. Epub 2014 Apr 29. Review.

20.

Plasmacytoid dendritic cells in the tumor microenvironment: immune targets for glioma therapeutics.

Candolfi M, King GD, Yagiz K, Curtin JF, Mineharu Y, Muhammad AK, Foulad D, Kroeger KM, Barnett N, Josien R, Lowenstein PR, Castro MG.

Neoplasia. 2012 Aug;14(8):757-70.

Supplemental Content

Support Center